FormaHoof Hoofcare Technology at the AAEP Convention: Is this hoof barefoot, shod...or protected?

FormaHoof is a new 3D hoof support process from Dubai. The hoof is not quite shod, and it's not exactly bare. Top farriers and equine podiatry veterinarians are singing FormaHoof's praises for not only the treatment capabilities of the molded coatings, but also the remarkable amount of sole growth and concavity they see at treatment's end. FormaHoof will be exhibiting at the American Association of Equine Practitioners Convention Trade Show, December 2-5 in San Francisco.

Whatever you call it, it has people talking. And looking. And asking questions. Until this week, FormaHoof seemed like just an interesting idea with a few slick videos on social media and a promise of results for rehabilitating hooves. “Liquid” horseshoes, some people called them. “Invisible” horseshoes, others said.

“3D” horseshoes?  We’ve heard that before, and can buy alternatives that claim the same effect, but for a lot less than the upfront investment in FormaHoof hoof treatment costs. Why, then, are farriers and veterinarians now buying and using the system?

Laminitis Survey Results: Do horse owners value science-based advice? Do they use it?

Equine research is fascinating, much-needed, and worthy of support. But are equine research findings being integrated into the care, feeding, and hoofcare of average horses? A survey in Great Britain set out to see if horse owners were applying research-based practices in their stable routines, using laminitis prevention as an example.

Palatable pergolide paste for PPID: BEVA award for Rendle presentation on clinical research into new treatment option for "equine cushings disease"

Many ponies and horses suffer from pituitary pars intermedia dysfunction (PPID), known in the past as equine cushings disease.  Among the common clinical signs of the endocrine-related condition, seen commonly in older (but not exclusively older) animals are long, non-shedding coats and chronic laminitis. PPID can, in most cases, be successfully managed by the medication pergolide mesylate, which is currently only FDA-approved in a poorly palatable tablet. A recent presentation on an alternative form of the medication has been recognized with a prize from the British Equine Veterinary Association.

Research into what may one day be a significant advance in options for the treatment of horses with pituitary pars intermedia dysfunction (PPID), once known as equine cushings disease, has received an award in the United Kingdom.